HAI Book 2025 - Flipbook - Page 10
Head-to-head comparison of longitudinal
plasma assays in relation to longitudinal
amyloid pathology in Alzheimer9s disease
........................................................... 516
Improving history-based prediction of
biomarker and clinical progression of
autosomal dominant Alzheimer9s disease
using mutation-level analysis of A´
production .......................................... 484
Soleimani-Meigooni, David ................ 520
Tau PET load in early- and late-onset
Alzheimer9s disease: A cross-sectional and
longitudinal comparison of the LEADS and
ADNI cohorts ...................................... 488
Calibration of multi-site raters for
prospective visual read of amyloid PET
scans acquired across the ADRC
Consortium for Clarity in ADRD Research
Through Imaging (CLARiTI) .................. 520
Chiotis, Konstantinos ........................ 488
Otero Svaldi, Diana............................. 492
Yang, Hyun-Sik ................................... 523
Regional tau quantiocation methodologies
in early symptomatic participants with
presence of tau pathology ................... 492
Plasma phosphorylated tau 217 and
longitudinal trajectories of A´, tau, and
cognition in cognitively unimpaired older
adults ................................................. 523
Franzmeier, Nicolai ............................ 496
Alpha Synuclein co-pathology accelerates
amyloid associated tau accumulation in
Alzheimer9s disease ............................. 496
Friday, January 17, 2025 - 09:00 am - 10:40 am ........ 499
Podium Session ....................................................... 499
SESSION VII: Factors which Influence ATN 499
Cohen, Ann ......................................... 500
Evaluating the ATN framework in a racially
and ethnically diverse cohort: Preliminary
analysis from the Health Aging Brain
Study- Health Disparities Study ........... 500
Molina-Henry, Doris ........................... 503
Friday, January 17, 2025 - 10:45 am - 11:40 am...........527
P3A: Poster Session 3A ...............................527
Vrillon, Agathe ................................... 533
117 Concordance between visual and
quantitative amyloid PET and CSF
biomarkers in the ADNI-DOD cohort......533
Soleimani-Meigooni, David ................ 537
118 Calibration of multi-site raters for
prospective visual read of amyloid PET
scans acquired across the ADRC
Consortium for Clarity in ADRD Research
Through Imaging (CLARiTI) ................... 537
Racial and ethnicity differences in plasma
biomarker eligibility prior to amyloid PET
imaging in the AHEAD 3-45 Study ........ 503
Pezzoli, Stefania ................................ 540
Examining neighborhood disadvantage as
a factor explaining amyloid onset age .. 505
Xiao, Yu .............................................. 543
Intersections of sex and neighborhood
disadvantage on Alzheimer9s disease
pathology............................................ 509
Ramirez Tirado, Laura Alejandra ....... 547
Heston, Margo .................................... 505
Reese, Alexandria .............................. 509
Coughlan, Gillian ................................. 512
Sex moderates relationships between PTau217 and longitudinal tau-PET: A multicohort study ........................................ 512
Friday, January 17, 2025 - 10:40 am - 10:45 am .......... 515
Podium Session ........................................................ 515
Blitz Session 3A: Short Poster Presentations
...................................................................... 515
Yakoub, Yara ....................................... 516
HAI2025 - 10
119 Evaluating the effect of APOE
genotype in real-world clinical settings:
results from the IDEAS-ANGI study ...... 540
120 Brain connectivity drives tau
distribution while regional vulnerability
drives tau load in Alzheimer9s disease .. 543
121 Synergistic effects of peripheral
innammation and neuroinnammation on
amyloid, vascular, and neurodegeneration
markers across the Alzheimer9s disease
spectrum............................................. 547
Tonietto, Matteo.................................. 551
122 Impact of amyloid removal on cerebral
volume changes with Gantenerumab .... 551
Schweitzer, Noah ............................... 554
